Format

Send to

Choose Destination
See comment in PubMed Commons below
Br J Clin Pharmacol. 2011 Jul;72(1):157-61. doi: 10.1111/j.1365-2125.2011.03980.x.

Does β-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study.

Author information

1
Division of Population Health Sciences and Education, St George's University of London, Tooting, London SW17 0RE, UK.

Abstract

AIMS:

To examine the effect of β-adrenoceptor blocker treatment on cancer survival.

METHODS:

In a UK primary care database, we compared patients with a new cancer diagnosis receiving β-adrenoceptor blockers regularly (n= 1406) with patients receiving other antihypertensive medication (n= 2056).

RESULTS:

Compared with cancer patients receiving other antihypertensive medication, patients receiving β-adrenoceptor blocker therapy experienced slightly poorer survival (HR = 1.18, 95% CI 1.04, 1.33 for all β-adrenoceptor blockers; HR = 1.21, 95% CI 0.94, 1.55 for non-selective β-adrenoceptor blockers). This poorer overall survival was explained by patients with pancreatic and prostate cancer with no evidence of an effect on survival for patients with lung, breast or colorectal cancer. Analysis in a cancer-free matched parallel cohort did not suggest selection bias masked a beneficial effect.

CONCLUSION:

Our study does not support the hypothesis that β-adrenoceptor blockers improve survival for common cancers.

PMID:
21453301
PMCID:
PMC3141198
DOI:
10.1111/j.1365-2125.2011.03980.x
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center